FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024

Rhea-AI Summary

FOXO Technologies Inc. (NYSE American: FOXO) has announced its 2024 Annual General Meeting of Shareholders, scheduled for December 31, 2024, at 9:30 am CST. The meeting will be conducted virtually via live webcast, with shareholders of record as of December 19, 2024, eligible to vote. CEO Seamus Lagan highlighted that FOXO has resolved all NYSE American listing deficiencies and acquired significant revenue-generating businesses. The company plans to hold an additional Special Meeting for other matters requiring shareholder approval. Management expressed optimism about their acquisition and growth strategy for 2025 and beyond.

Positive

• All NYSE American listing deficiencies have been resolved
• Acquisition of revenue-generating businesses completed
• Growth strategy in place for 2025

Negative

• Additional Special Meeting required for pending shareholder approvals

MINNEAPOLIS, MN, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its 2024 Annual General Meeting of its Shareholders at 9:30 am CST on Tuesday, December 31, 2024.

The Annual General Meeting will be a completely virtual meeting of its stockholders, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, vote and submit your questions during the Annual Meeting by first registering at https://web.viewproxy.com/FOXO/2024

Shareholders of record on December 19, 2024, will be entitled to vote on the proposals. All shareholder votes are important.

The Board of Directors asks that all shareholders vote in favor of the proposals listed on the Proxy Card filed as part of the Definitive Proxy Statement filed with the Securities and Exchange Commission and appreciates continued support from its shareholders.

“We look forward to ending the year with our 2024 Annual General Meeting to have our shareholders approve our directors and auditors,” said Seamus Lagan, CEO of FOXO. “We will also require another Special Meeting as soon as practical for other matters needing shareholder approval.” Mr. Lagan continued with, “2024 has been a transformative year for FOXO. We are ending the year with all deficiencies for our NYSE American continued listing requirements fixed, significant revenue generating businesses acquired and an acquisition and growth strategy that we believe will propel significant growth and value in 2025 and beyond.”

About FOXO Technologies Inc. (“FOXO”)

FOXO owns and operates three subsidiaries.

Foxo Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services.

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.

For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about the delisting of the Warrants from NYSE American, trading of the Warrants in the over-the-counter market, the continued listing of the Company’s Class A common stock on NYSE American, and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. Any such forward-looking statements are based upon the current beliefs and expectations of the Company’s management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company’s control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the possibility that the Plan will not be accepted by NYSE American, the Company will be unable to satisfy other continued listing requirements of NYSE American for its Class A common stock to maintain the listing of the Class A common stock on NYSE American; the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com

FAQ

When is FOXO Technologies' 2024 Annual General Meeting?

FOXO Technologies' 2024 Annual General Meeting will be held virtually on December 31, 2024, at 9:30 am CST.

What is the record date for FOXO shareholders to vote at the 2024 Annual Meeting?

Shareholders of record as of December 19, 2024, will be entitled to vote at the Annual Meeting.

Has FOXO resolved its NYSE American listing deficiencies?

Yes, according to CEO Seamus Lagan, FOXO has fixed all deficiencies for NYSE American continued listing requirements.

What major developments did FOXO achieve in 2024?

In 2024, FOXO resolved NYSE American listing deficiencies and acquired significant revenue-generating businesses.

Will FOXO hold additional shareholder meetings beyond the 2024 Annual Meeting?

Yes, FOXO plans to hold an additional Special Meeting as soon as practical for other matters requiring shareholder approval.